-
IPH45 abstract selected for oral presentation at the 2024 AACR Annual Meeting
-
Preclinical data support further development of IPH45; Differentiated topoisomerase I inhibitor ADC targeting nectin-4 progressing towards the clinic
Marseille, France, March 6, 2024–(BUSINESS WIRE)–Regulatory news:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“congenital” or “company“) today announced that an abstract on its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4, has been recognized as a 2024 American Association for Cancer Research (AACR) We announced that we have been selected to give an oral presentation at the next general meeting, which will be held from April 5th to 10th in San Diego, California.
“We are pleased to present our findings on IPH45 at this year's AACR. IPH45 is the most advanced ADC to deliver topoisomerase I inhibitors to tumors expressing Nectin-4. Our research We demonstrate that IPH45 effectively inhibits tumor growth both in vitro and in vivo, and exhibits a favorable safety profile in preclinical studies.,” said Professor Eric Vivier, DVM, PhD, Chief Scientific Officer, Innate Pharma. ”These promising results highlight the potential of IPH45 and reflect our dedication to pioneering the next wave of cancer treatments through advanced antibody engineering. Based on these promising data, we are enthusiastically advancing his IPH45 towards clinical trials.. ”
Presentation details
For more information, please visit the AACR website.
About IPH45
Nectin-4 is a cell membrane adhesion protein that is overexpressed in several solid tumors, including urothelial cancer, breast cancer, lung cancer, ovarian cancer, and pancreatic cancer, but has limited expression in normal tissues. IPH45 is a novel topoisomerase I inhibitor antibody-drug conjugate (ADC) that targets Nectin-4.In non-clinical models, IPH45 is well tolerated and exhibits antitumor effects in vitro and in vivo. IPH45 is on track for first place in human research.
About Innate Pharma
Innate Pharma SA is a global clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET.® (aantibody-based N.K. cell Engar Therapeutics) proprietary platform.
Innate's portfolio includes leading proprietary programs racutamab, developed in advanced forms of cutaneous and peripheral T-cell lymphoma, monalizumab, developed with AstraZeneca in non-small cell lung cancer, and ANKET .® Multispecific NK cell engagers to address multiple tumor types.
As a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca and leading research institutions, Innate Pharma accelerates innovation, research and development for the benefit of patients.
Headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, Innate Pharma is listed on Euronext Paris and Nasdaq in the United States.
For more information about Innate Pharma, please visit www.innate-pharma.com. follow me. twitter And LinkedIn.
Innate Pharma stock information
ISIN code |
FR0010331421 |
|
ticker code |
Euronext: IPH Nasdaq: IPHA |
|
Ray |
9695002Y8420ZB8HJE29 |
Disclaimer Regarding Forward-Looking Information and Risk Factors
This press release contains certain forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words such as “believes,” “may,” “expects,” “will” and similar expressions are intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from expectations. . These risks and uncertainties include uncertainties inherent in research and development, including safety, the progress and results of ongoing and planned clinical trials and preclinical studies, and regulatory review and approval of product candidates. included. the Company's commercialization efforts and continued ability to obtain financing to fund development; Please see the “Risk Factors” section for additional discussion of risks and uncertainties that could cause the Company's actual results, financial condition, performance and achievements to differ from those contained in the forward-looking statements. please refer to. A universal registration document filed with the French Financial Market Authority (“AMF”) (available on the AMF website http://www.amf-france.org or Innate Pharma’s website), and filed with the U.S. Securities Public documents and reports filed by the Company, including the Company's Annual Report on Form 20-F for the year ended December 31, 2022, and any subsequent public documents filed with the AMF or the SEC or published by the Company. Includes submissions and reports.
This press release and the information contained herein does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for, any shares of Innate Pharma in any country.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240305421795/ja/
contact address
For more information, please contact us below.
Investor
Innate Pharma
henry wheeler
Phone number: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media contact point
new cap
Arthur Louiet
Phone number: +33 (0)1 44 71 00 15
innate@newcap.eu